Skip to main content
Season 3 ends in 25 d 11:42:26 $2,000 10,000 pts = 1 month Premium
Health & Medicine

Asundexian FDA Approval: Sunharbo Stroke Pill Explained

Published 12 min read
Open the post and read it to claim 30 points
A white tablet in front of a brain model with glowing arteries, illustrating asundexian (Sunharbo) for stroke prevention

Sign in and earn +30 points by reading this

Read to the end, wait a few seconds, then tap the claim button below.

In short

As of 13 November 2026, the US FDA has approved Sunharbo (asundexian), the first factor XIa inhibitor, for use with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk TIA [1]. In the OCEANIC-STROKE trial it cut ischaemic stroke by 26% versus placebo [1][2].

Key takeaways

  1. The FDA approved Sunharbo (asundexian) 50 mg tablets on 9 November 2026, the first factor XIa inhibitor approved in the US [1][3].
  2. It is approved only in combination with antiplatelet therapy, for adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA) [1].
  3. In the 12,327-patient OCEANIC-STROKE trial, ischaemic stroke occurred in 6.2% on asundexian and 8.4% on placebo [2].
  4. Major bleeding was similar overall (1.9% vs 1.7%), but the FDA says it was higher in people over 75 and in the first 90 days [1][2].
  5. Sunharbo is not approved for stroke prevention in atrial fibrillation; an earlier trial in that group was stopped after more strokes than with apixaban [1][4].
  6. China approved it on 26 October 2026; the EMA and Japan are still reviewing it, according to Bayer [3].
On this page 11 sections
  1. What is asundexian (Sunharbo)?
  2. Who is Sunharbo approved for?
  3. What did the OCEANIC-STROKE trial show?
  4. What are the bleeding and other risks?
  5. Why is Sunharbo not approved for atrial fibrillation?
  6. When will Sunharbo be available?
  7. What should you do if stroke symptoms appear?
  8. Common mistakes
  9. Frequently asked questions
  10. Glossary
  11. Sources

What is asundexian (Sunharbo)?

Asundexian, sold as Sunharbo, is an oral tablet that blocks activated factor XI (factor XIa), a protein in the blood-clotting process; the FDA calls it the first factor XIa inhibitor it has approved [1].

Bayer, which makes the drug, says factor XIa inhibition "reduces amplification of thrombin generation", thrombin being a key enzyme in forming clots [3]. It describes Sunharbo as first-in-class and once daily [3].

  • Why factor XI: the NEJM trial paper notes that low factor XI levels are associated with a reduced risk of ischaemic stroke [2]. This is an association from population data, not proof on its own.
  • The hoped-for advantage: Bayer says that in preclinical models (laboratory and animal studies) factor XIa inhibition targets harmful clotting more than the normal clotting that stops bleeding [3]. Preclinical findings do not show the same effect in people.
  • Strength approved: the FDA approval covers 50 mg tablets, the strength tested in the pivotal trial [1][2].

The FDA granted Sunharbo Fast Track and Priority Review designations, and the approval went to Bayer HealthCare Pharmaceuticals in Whippany, New Jersey [1].

Hylton Joffe, director of the FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, said the approval "represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention" [1].

Red blood cells and platelets caught in a fibrin mesh inside an artery, showing the clotting that factor XIa inhibitors target
Factor XIa helps amplify thrombin generation and clot formation.

Who is Sunharbo approved for?

The FDA label is narrow: adults who have had a recent mild-to-moderate non-cardioembolic ischaemic stroke (NIH Stroke Scale 15 or lower) or a high-risk TIA, and only in combination with antiplatelet therapy [1].

  • Non-cardioembolic stroke: the FDA explains this as a stroke caused by a clot that did not originate in the heart [1].
  • High-risk TIA: a transient ischaemic attack, often called a "mini-stroke" [1]. CDC describes a TIA as stroke symptoms that go away after a few minutes, and says it is a sign of a serious condition [6].
  • Add-on, not replacement: in the trial, both groups also took antiplatelet therapy, and the approval is for use alongside it [1][2].
  • Not for atrial fibrillation: the FDA states that Sunharbo is not approved for stroke prevention in patients with atrial fibrillation [1].

The trial enrolled patients within 72 hours of symptom onset who also had at least one of: a non-lacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging [2]. The mean age at enrolment was 68 years, according to Bayer [3].

Repeat strokes are common. CDC says that of more than 795,000 strokes in the United States each year, about 185,000, nearly 1 in 4, are in people who have had a previous stroke, and about 87% of all strokes are ischaemic [5].

What did the OCEANIC-STROKE trial show?

Among 12,327 patients, ischaemic stroke occurred in 6.2% on asundexian and 8.4% on placebo, a hazard ratio of 0.74, which the FDA describes as a 26% reduction over a median treatment of 14.2 months [1][2].

OCEANIC-STROKE was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial, published in the New England Journal of Medicine and funded by Bayer [1][2]. Patients were assigned 6,162 to asundexian and 6,165 to placebo, in addition to planned single or dual antiplatelet therapy [2].

  • Primary result: ischaemic stroke 6.2% versus 8.4% (hazard ratio 0.74; 95% CI 0.65 to 0.84) [2].
  • All strokes: 6.6% versus 8.8%, driven mainly by fewer ischaemic strokes, according to Bayer [3].
  • Heart attack, stroke or cardiovascular death: the composite was lower with asundexian [2]; Bayer gives 9.2% versus 11.1% [3].
  • Adverse events overall: 69.3% with asundexian and 70.1% with placebo; serious adverse events 19.2% and 19.5% [2].

The trial compared asundexian with placebo on top of antiplatelet therapy, not with other anticoagulants, so it does not show how it compares with them in this group [2].

The table below sets out the main figures.

Two identical plain white pill bottles on a hospital pharmacy counter, representing the placebo-controlled OCEANIC-STROKE trial
OCEANIC-STROKE compared asundexian with placebo, both on top of antiplatelet therapy.

What are the bleeding and other risks?

Major bleeding was similar overall, 1.9% with asundexian and 1.7% with placebo, but the FDA says it was increased in patients older than 75 and during the first 90 days of treatment [1][2].

Bayer's prescribing summary gives major bleeding rates per 100 patient-years for these groups [3]:

  • Overall: 1.6 versus 1.5 [3].
  • First 90 days: 4.5 versus 3.1 [3].
  • Older than 75: 2.6 versus 1.7 [3].
  • High-risk TIA subgroup: 2.9 versus 1.0 [3].
  • Gastrointestinal bleeding: 2.7 versus 2.1; the FDA also says it occurred more often with Sunharbo [1][3].

Other points from the FDA announcement [1]:

  • The most common adverse reaction, in 3% or more of patients, was diarrhoea; Bayer gives 3.4% versus 2.8% [1][3].
  • Use with medicines that are combined P-gp and strong CYP3A4 inducers, such as carbamazepine, is not recommended because they may reduce its effect [1].
  • It is not recommended in moderate or severe liver impairment [1]. Bayer says it is associated with raised liver enzymes, and that serious liver injury with jaundice was reported in less than 0.02% of treated patients [3].
  • It should be withheld at least 24 hours before elective surgery or invasive procedures, and for at least 24 hours after clot-busting treatment (thrombolysis) for acute stroke [1].

Bayer also says breastfeeding is not recommended during treatment and for 5 days after the last dose [3].

Why is Sunharbo not approved for atrial fibrillation?

In the OCEANIC-AF trial of 14,810 people with atrial fibrillation, asundexian led to more strokes or systemic embolism than the standard anticoagulant apixaban, 1.3% versus 0.4%, and the trial was stopped early [4].

The approved label covers strokes caused by a clot that did not originate in the heart [1]; people with atrial fibrillation were studied separately. The NEJM paper on OCEANIC-AF, published in 2024, reported [4]:

  • Efficacy: stroke or systemic embolism in 98 patients (1.3%) on asundexian and 26 (0.4%) on apixaban, a hazard ratio of 3.79 [4].
  • Bleeding: major bleeding in 17 patients (0.2%) on asundexian and 53 (0.7%) on apixaban [4].
  • Stopping: the independent data monitoring committee recommended stopping the trial early [4].

The FDA states plainly that Sunharbo is not approved for stroke prevention in atrial fibrillation [1]. For background on why AI chatbots can get health and drug details wrong, see AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers.

A 3D model of the human heart with the left atrial appendage highlighted, illustrating atrial fibrillation
The FDA says Sunharbo is not approved for stroke prevention in atrial fibrillation.

When will Sunharbo be available?

Bayer says Sunharbo should begin shipping in mid-to-late November 2026 and become available for US hospitals and pharmacies to order shortly after [3].

  • United States: approved by the FDA on 9 November 2026 [1].
  • China: approved by the National Medical Products Administration on 26 October 2026, according to Bayer [3].
  • Europe and Japan: under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare as of November 2026, Bayer says [3].
  • Cost: a Bayer spokesperson said a 30-day supply will have a list price of $748.50, as reported on 9 November 2026 [7]. Bayer also says the list price does not reflect what most health plans or patients will pay, and that some patients may be able to get the drug for free through the Bayer US Patient Assistance Foundation [8].

Bayer quotes Ashkan Shoamanesh, co-principal investigator of OCEANIC-STROKE, saying the risk of another stroke "is highest in the days and weeks after the initial event, and that risk persists over time" [3]. Shoamanesh is a trial investigator, and the announcement is from the manufacturer [3].

Patients sharing their medical history with AI tools to research new drugs should know how that data may be used, as covered in Is ChatGPT Safe for Your Privacy? What AI Chatbots Do With the Data You Share.

What should you do if stroke symptoms appear?

CDC says to call 9-1-1 right away for sudden stroke signs, because the treatments that work best are available only if a stroke is recognised and diagnosed within 3 hours of the first symptoms [6].

CDC's B.E. F.A.S.T. check [6]:

  • B, balance: sudden loss of balance or dizziness [6].
  • E, eyes: sudden trouble seeing [6].
  • F, face: one side of the face droops when the person smiles [6].
  • A, arms: one arm drifts down when both are raised [6].
  • S, speech: slurred or strange speech [6].
  • T, time: call 9-1-1 and note when symptoms began [6].

CDC also advises calling an ambulance rather than driving to hospital, and telling a health care team right away about symptoms that went away after a few minutes, since that may have been a TIA [6].

Sunharbo is approved to reduce the risk of stroke after a recent stroke or TIA [1]; for new symptoms, CDC's advice is to call 9-1-1 [6]. What AI tools can and cannot do in health care, and how they are regulated, is covered in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.

This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.

OCEANIC-STROKE: asundexian vs placebo, both with antiplatelet therapy (NEJM 2026; FDA; Bayer)
OutcomeAsundexianPlaceboSource
Ischaemic stroke6.2%8.4%[2]
All strokes6.6%8.8%[3]
CV death, heart attack or stroke9.2%11.1%[3]
Major bleeding1.9%1.7%[2]
Serious adverse events19.2%19.5%[2]
Diarrhoea3.4%2.8%[3]

Common mistakes

  • Thinking Sunharbo replaces aspirin or clopidogrel

    Fix: It is approved only in combination with antiplatelet therapy [1].

  • Assuming it is for atrial fibrillation

    Fix: The FDA says it is not approved for stroke prevention in atrial fibrillation [1].

  • Reading 'similar bleeding' as no extra risk

    Fix: Major bleeding rose in people over 75 and in the first 90 days [1].

  • Expecting it in Europe now

    Fix: Bayer says the EMA is still reviewing it [3].

  • Treating it as an emergency stroke treatment

    Fix: It is for reducing the risk of another stroke; CDC says to call 9-1-1 for symptoms [1][6].

Frequently asked questions

What is asundexian (Sunharbo)?

An oral factor XIa inhibitor; the FDA's first approved drug in that class [1].

Who is Sunharbo approved for?

Adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk TIA, with antiplatelet therapy [1].

What did the OCEANIC-STROKE trial show?

Ischaemic stroke in 6.2% on asundexian versus 8.4% on placebo [2].

What are the bleeding and other risks?

Major bleeding was similar overall but higher over age 75 and in the first 90 days; diarrhoea was most common [1].

Why is Sunharbo not approved for atrial fibrillation?

OCEANIC-AF found more strokes with asundexian than apixaban and stopped early [4].

When will Sunharbo be available?

Bayer expects US shipping from mid-to-late November 2026; EMA review continues [3].

What should you do if stroke symptoms appear?

CDC says call 9-1-1 right away and note when symptoms started [6].

Glossary

Factor XIa
The activated form of clotting factor XI, which helps amplify clot formation.
Ischaemic stroke
A stroke caused by blocked blood flow to part of the brain.
Non-cardioembolic
Caused by a clot that did not come from the heart.
TIA
Transient ischaemic attack: brief stroke symptoms that resolve, often called a mini-stroke.
Antiplatelet therapy
Medicines such as aspirin that stop platelets clumping.
Hazard ratio
The relative rate of an event in one group versus another over time.

Sources

  1. FDA Approves First Factor XIa Inhibitor to Help Prevent Stroke in Certain Adults at High Risk US Food and Drug Administration · 2026-11-09
  2. Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) New England Journal of Medicine · 2026-04-15
  3. Bayer's SUNHARBO (asundexian) approved by the U.S. FDA Bayer · 2026-11-09
  4. Asundexian versus Apixaban in Patients with Atrial Fibrillation (OCEANIC-AF) New England Journal of Medicine · 2024-09-01
  5. Stroke Facts CDC · 2024-10-24
  6. Signs and Symptoms of Stroke CDC · 2026-05-19
  7. Bayer wins FDA nod for a new kind of blood thinner BioPharma Dive · 2026-11-09
  8. Asundexian Is the First Factor XIa Inhibitor to Gain FDA Approval TCTMD · 2026-11-10
Share this guide Telegram WhatsApp X
0 likes

Comments

Top comments

About the Pouyam Team Editorial policy

On Pouyam

Explore Pouyam

Guides are one corner of Pouyam. Here is where to go next.

Quick navigation